Quick Login
CLOSE X
FRR FAMILY
FRR BOSS NEW
TRAINEE MILLIONAIRE
FRR FOREX
FRRBOSS SHAREPRO
Equity
Home/ Are You A Trader/  Market Info/  Company Profile/  Smart Quotes

SANOFI INDIA LTD.

NSE : SANOFIBSE : 500674ISIN CODE : INE058A01010Industry : Pharmaceuticals & DrugsHouse : Sanofi India - MNC
BSE6263.503.95 (+0.06 %)
PREV CLOSE (Rs.) 6259.55
OPEN PRICE (Rs.) 6244.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 336
TODAY'S LOW / HIGH (Rs.)6238.35 6314.50
52 WK LOW / HIGH (Rs.)4145.9 10526.05
NSE6275.5010.5 (+0.17 %)
PREV CLOSE( Rs. ) 6265.00
OPEN PRICE (Rs.) 6265.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 4034
TODAY'S LOW / HIGH(Rs.) 6205.00 6317.00
52 WK LOW / HIGH (Rs.)4902 10524.95

Smart Quotes

BSE NSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs)
21.07
Dividend Yield(%)
1.87
TTM EPS (Rs.)
156.83
P/E Ratio
39.94
Book Value (Rs.)
395.40
Face Value (Rs.)
10
MCap (Rs. in Mn)
144252.30
Price/Earning (TTM)
36.21
Price/Sales (TTM)
7.08
Price/Book (MRQ)
15.84
PAT Margin (%)
15.20
ROCE (%)
46.15
Incorporation Year : 02-05 1956

Management Info :

Aditya Narayan - Chairman - Managing Director

Registered Office :

Address : Sanofi House, C T S No. 117- B,L & T Business Park,Saki Vihar Road, Powai,
Mumbai,
Maharashtra-400072

Phone :  022-2803 2000

Registrars Details :

MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE
NEWS
25Apr Sanofi India informs about disclosure
In compliance with Regulation 30 of the SEBI (LODR) Regulations, Sanofi..
24Apr Sanofi India informs about disclosure
In compliance with Regulation 30 of the SEBI (LODR) Regulations, Sanofi..
16Apr Sanofi India informs about press release
Sanofi India has informed that it enclosed copies of the newspaper adver..
more
Financials
QTR Mar 25 ANNUAL 24
Net Profit11954135
Gross Profit 1653 4314
Operating Profit 1752 5073
Net Sales 5359 20132
more
Rs. in Millions
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Emcure Pharma (BSE)
 1288.65 (10.00%)
M.Cap (Rs. in Cr)24417.77
Medplus Health Servi (BSE)
 950.90 (7.36%)
M.Cap (Rs. in Cr)11381.69
Shilpa Medicare (BSE)
 781.50 (6.33%)
M.Cap (Rs. in Cr)7642.36
Orchid Pharma (BSE)
 754.40 (4.21%)
M.Cap (Rs. in Cr)3826.25
Shareholding Pattern
PROMOTERS
60.4%
FI/BANKS/INSURANCE
11.75%
MUTUAL FUNDS/UTI
11.26%
NON-INSTITUTION
11.01%
GOVERNMENT
0%
FII
0%
more
Mf Holding
Attention Investors KYC ASBA

Attention Investors

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month, Issued in the interest of Investors.

Privacy | Disclaimer | Copyright | Terms & Conditions | Investor Grievance | Advisory for Investor | Investor Charter And Complaints | Investor SEBI Scores |
Regulatory Information | Documents in Vernacular Languages | CDSL E-Voting | Link Pan and Aadhaar | Fund Transfer | Segregation And Monitoring Of Collateral At Client Level |
Risk Disclosure on Derivatives | Smart ODR | Mandatory Display | KYC Validation Links
BSE / NSE SEBI Registration No. INZ000279232, Depository Participant SEBI Registration No. – IN DP CDSL 132-2015
Mutual funds - ARN No. 81648 , Investment Adviser SEBI Registration No. : INA000008668.
© 2015 FRR Shares. All Rights Reserved | Designed, Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.
close X

Download Client Registration Documents

Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do's & Don't's) in Vernacular Language :
Assamese Bengali Gujarati Hindi Kanada
Kashmiri Konkani Malyalam Marathi Oriya
Punjabi Sindhi Tamil Telegu Urdu

NOTE : " This document is a translated version of the client registration documents in English and is being provided in vernacular language to facilitate better understanding by the investors. In case of any ambiguity, the contents of the English version would prevail. "